This protocol addresses acute liver failure (ALF) arising specifically from reactivation of hepatitis B virus (HBV). HBV reactivation is a recognised cause of ALF and requires prompt recognition and a targeted treatment approach distinct from other aetiologies of acute liver failure.
In this setting, initiation of antiviral therapy — specifically a nucleoside analog — is a key component of management. The complete regimen, including agent selection criteria and the full clinical algorithm, is available in the structured protocol.